These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23859312)

  • 21. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome.
    Watt KD; Lyden ER; Gulizia JM; McCashland TM
    Liver Transpl; 2006 Jan; 12(1):134-9. PubMed ID: 16382465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution.
    Zekry A; Whiting P; Crawford DH; Angus PW; Jeffrey GP; Padbury RT; Gane EJ; McCaughan GW;
    Liver Transpl; 2003 Apr; 9(4):339-47. PubMed ID: 12682883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data.
    Gupta G; Kang L; Yu JW; Limkemann AJ; Garcia V; Bandyopadhyay D; Kumar D; Fattah H; Levy M; Cotterell AH; Sharma A; Bhati C; Reichman T; King AL; Sterling R
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28712111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome.
    Yoo HY; Maheshwari A; Thuluvath PJ
    Liver Transpl; 2003 Sep; 9(9):897-904. PubMed ID: 12942450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome.
    Carmiel-Haggai M; Fiel MI; Gaddipati HC; Abittan C; Hossain S; Roayaie S; Schwartz ME; Gondolesi G; Emre S; Schiano TD
    Liver Transpl; 2005 Dec; 11(12):1567-73. PubMed ID: 16315297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection.
    Neff GW; O'Brien CB; Nery J; Shire NJ; Nishida S; delaGarza J; Montalbano M; Safdar K; Ruiz P; Rideman E; Gascon JA; Tzakis AG; Madariaga J; Rudich SM
    Liver Transpl; 2004 Dec; 10(12):1497-503. PubMed ID: 15558835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The natural history of hepatitis C virus in pediatric liver transplant recipients.
    Barshes NR; Udell IW; Lee TC; O'Mahony CA; Karpen SJ; Carter BA; Goss JA
    Liver Transpl; 2006 Jul; 12(7):1119-23. PubMed ID: 16799942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study.
    McCashland T; Watt K; Lyden E; Adams L; Charlton M; Smith AD; McGuire BM; Biggins SW; Neff G; Burton JR; Vargas H; Donovan J; Trotter J; Faust T
    Liver Transpl; 2007 Sep; 13(9):1246-53. PubMed ID: 17763405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C is a risk factor for death after liver retransplantation.
    Pelletier SJ; Schaubel DE; Punch JD; Wolfe RA; Port FK; Merion RM
    Liver Transpl; 2005 Apr; 11(4):434-40. PubMed ID: 15776460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.
    Berenguer M; Prieto M; San Juan F; Rayón JM; Martinez F; Carrasco D; Moya A; Orbis F; Mir J; Berenguer J
    Hepatology; 2002 Jul; 36(1):202-10. PubMed ID: 12085366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of live donor liver transplantation in patients with hepatitic C virus infection: the HCV 3 trial experience.
    Sher L; Jennings L; Rudich S; Alexopoulos SP; Netto G; Teperman L; Kinkhabwala M; Brown RS; Pomfret E; Klintmalm G;
    Clin Transplant; 2012; 26(3):502-9. PubMed ID: 22151078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database.
    Charlton M; Ruppert K; Belle SH; Bass N; Schafer D; Wiesner RH; Detre K; Wei Y; Everhart J
    Liver Transpl; 2004 Sep; 10(9):1120-30. PubMed ID: 15350002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver transplantation from anti-hepatitis C virus-positive donors: our experience.
    Álvaro E; Abradelo M; Fuertes A; Manrique A; Colina F; Alegre C; Calvo J; García M; García-Sesma A; Cambra F; Sanabria R; Moreno E; Jimenez C
    Transplant Proc; 2012; 44(6):1475-8. PubMed ID: 22841188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation.
    Ercolani G; Grazi GL; Ravaioli M; Del Gaudio M; Cescon M; Varotti G; Ramacciato G; Vetrone G; Zanello M; Pinna AD
    Liver Transpl; 2006 Jul; 12(7):1104-11. PubMed ID: 16710855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
    Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
    Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database.
    Watt KD; Dierkhising R; Heimbach JK; Charlton MR
    Liver Transpl; 2012 Sep; 18(9):1029-36. PubMed ID: 22641474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.
    Burra P; Loreno M; Russo FP; Germani G; Galligioni A; Senzolo M; Cillo U; Zanus G; Fagiuoli S; Rugge M
    Liver Transpl; 2009 Jun; 15(6):619-28. PubMed ID: 19479805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retransplantation for recurrent hepatitis C: positive aspects.
    McCashland TM
    Liver Transpl; 2003 Nov; 9(11):S67-72. PubMed ID: 14586899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients.
    Maluf DG; Edwards EB; Stravitz RT; Kauffman HM
    Liver Transpl; 2009 Jun; 15(6):592-9. PubMed ID: 19479802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.